Trial Profile

Randomized, blinded, active-controlled Phase II clinical trial of ReCOV on healthy subjects who have received primary vaccination with two doses of an inactivated COVID-19 vaccine compared with Pfizer's mRNA vaccine COMIRNATY

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Recombinant two component COVID 19 vaccine Jiangsu Rec Biotechnology (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics

25 Dec 2022 Results published in the Jiangsu Recbio Media Release
18 Aug 2022 According to Jiangsu Recbio Technology media release, enrollment and dosing has been completed in this trial in around two weeks from the receipt of clinical trial approval .
18 Aug 2022 Status changed from planning to active, no longer recruiting, according to a Jiangsu Recbio Technology media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com